Details of Disease

General Information of Disease (ID: DIS17AI2)

• Disease Name: T-cell acute lymphoblastic leukaemia
• Synonyms: acute T cell leukaemia; acute T-cell lymphoblastic leukaemia; precursor T-lymphoblastic leukemia (T-cell ALL); acute T-cell lymphocytic leukaemia; T acute lymphoblastic leukaemia; acute T-cell leukemia; T-cell ALL; T acute lymphoblastic leukemia; acute T cell lymphoblastic leukemia; acute T cell lymphoblastic leukaemia; T-cell acute lymphocytic leukemia; T-cell type acute leukaemia; precursor T-lymphoblastic leukaemia (T-cell ALL); T-cell acute lymphocytic leukaemia; acute T cell lymphocytic leukemia; T-cell acute lymphoblastic leukemia; acute T-cell lymphocytic leukemia; acute T cell leukemia; precursor T-lymphoblastic leukemia; acute T cell lymphocytic leukaemia; T-ALL; T-cell acute lymphoblastic leukaemia; T-cell type acute leukemia; acute T-cell lymphoblastic leukemia; acute T-cell leukaemia; precursor T lymphoblastic leukemia; precursor T-lymphoblastic leukaemia; precursor T lymphoblastic leukaemia
• Disease Class: 2A90: Mature T-cell lymphoma
• Definition: Acute lymphoblastic leukemia of T-cell origin. It comprises about 15% of childhood cases and 25% of adult cases. It is more common in males than females. (WHO, 2001)
• Disease Hierarchy:
  DISJ6YIF: T-cell leukaemia
  DIS87TGM: Acute lymphoblastic leukaemia
  DIS17AI2: T-cell acute lymphoblastic leukaemia
• ICD Code:
  ICD-11: ICD-11: 2A90.5
  ICD-10: ICD-10: C91.5
• Disease Identifiers:
  MONDO ID: MONDO_0004963
  MESH ID: D054218
  UMLS CUI: C1961099
  MedGen ID: 368378
  HPO ID: HP:0006727
  SNOMED CT ID: 128824003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Nelarabine	DMB6VEG	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
LY3039478	DMC5SAW	Phase 1/2	Small molecular drug	[2]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 85 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABL2	TT1A6HL	Limited	Genetic Variation	[3]
CD2	TTJDUNO	Limited	Biomarker	[4]
CD3E	TTZAT79	Limited	Genetic Variation	[5]
CDKN2C	TTBRUGA	Limited	Biomarker	[6]
FCGRT	TTKLPHO	Limited	Genetic Variation	[7]
HOXA11	TTEX4ZA	Limited	Altered Expression	[8]
HOXA13	TTN26OM	Limited	Genetic Variation	[9]
LCK	TT860QF	Limited	Biomarker	[10]
MAP3K10	TT9FN4J	Limited	Biomarker	[11]
MTOR	TTCJG29	Limited	Genetic Variation	[12]
MTTP	TTUS1RD	Limited	Biomarker	[13]
NKX3-1	TT1E0JK	Limited	Altered Expression	[14]
PINX1	TT4FJ3A	Limited	Biomarker	[15]
S100A4	TTPR5SX	Limited	Genetic Variation	[16]
TRBC1	TT1DHW2	Limited	Genetic Variation	[14]
FCER2	TTCH6MU	Disputed	Biomarker	[17]
BAX	TTQ57WJ	moderate	Genetic Variation	[18]
SMARCA4	TTVQEZS	moderate	Biomarker	[19]
ABCG2	TTIMJ02	Strong	Posttranslational Modification	[20]
ARRB1	TTMVD4A	Strong	Biomarker	[21]
ASRGL1	TT4WT91	Strong	Altered Expression	[22]
AVPR2	TTK8R02	Strong	Biomarker	[23]
BCL2	TTFOUV4	Strong	Biomarker	[24]
BCL6	TTC9YX5	Strong	Biomarker	[25]
CCND3	TT1JXNR	Strong	Altered Expression	[26]
CCR9	TTIPS8B	Strong	Biomarker	[27]
CD1A	TTBGTFN	Strong	Biomarker	[28]
CD22	TTM6QSK	Strong	Genetic Variation	[29]
CD33	TTJVYO3	Strong	Altered Expression	[30]
CD34	TTZAVYN	Strong	Biomarker	[31]
CD38	TTPURFN	Strong	Altered Expression	[32]
CD46	TTMS7DF	Strong	Biomarker	[33]
CHKA	TT10AWB	Strong	Altered Expression	[34]
CRLF2	TTRMZ0N	Strong	Altered Expression	[35]
CXCR4	TTBID49	Strong	Biomarker	[36]
DLL1	TT9CFQD	Strong	Genetic Variation	[37]
DLL4	TTV23LH	Strong	Biomarker	[38]
DNM2	TTVRA5G	Strong	Altered Expression	[39]
F2RL3	TTD0652	Strong	Biomarker	[40]
HMGA1	TTBA219	Strong	Altered Expression	[41]
HNMT	TT2B6EV	Strong	Biomarker	[42]
HOXA7	TTMRE4Q	Strong	Posttranslational Modification	[43]
IKZF3	TTCZVFZ	Strong	Biomarker	[44]
IL3RA	TTENHJ0	Strong	Biomarker	[45]
IL7	TT8FRMO	Strong	Genetic Variation	[46]
IL7R	TTAWI51	Strong	Biomarker	[46]
IRAK1	TTXAJWN	Strong	Biomarker	[47]
JAK3	TTT7PJU	Strong	Genetic Variation	[48]
KDM6B	TTDIJUQ	Strong	Biomarker	[49]
KMT2A	TT1GNDM	Strong	Biomarker	[50]
MALT1	TTCI81G	Strong	Biomarker	[51]
MTAP	TTDBX7N	Strong	Biomarker	[52]
MYB	TT8V13P	Strong	Biomarker	[53]
MYCN	TT9JBY5	Strong	Biomarker	[19]
NOTCH3	TTVX7IA	Strong	Biomarker	[54]
PAWR	TT3I4WV	Strong	Biomarker	[40]
PAX5	TTA4REJ	Strong	Altered Expression	[55]
PMEL	TT8MK59	Strong	Biomarker	[56]
PRKCQ	TT1MS7X	Strong	Biomarker	[57]
PSMB6	TT8EPLT	Strong	Genetic Variation	[37]
PTK7	TTXH2ZN	Strong	Biomarker	[58]
PTPN2	TTY8PUS	Strong	Biomarker	[59]
RBPJ	TT72D4Z	Strong	Altered Expression	[60]
RUNX1	TTWIN3H	Strong	Altered Expression	[61]
STAT1	TTN7R6K	Strong	Biomarker	[62]
TCL1A	TTUKRDV	Strong	Genetic Variation	[63]
TNFRSF10B	TTW20TU	Strong	Altered Expression	[64]
TRB	TT84HCW	Strong	Genetic Variation	[65]
TRIM59	TT613U4	Strong	Biomarker	[66]
TYK2	TTBYWP2	Strong	Biomarker	[23]
USP7	TTXU3EQ	Strong	Altered Expression	[67]
CA12	TTSYM0R	Definitive	Altered Expression	[68]
CD47	TT28S46	Definitive	Biomarker	[69]
CD5	TTEGYK1	Definitive	Altered Expression	[70]
CTCFL	TTY0RZT	Definitive	Altered Expression	[71]
DEPTOR	TTLYP6D	Definitive	Biomarker	[72]
EPHB6	TTZEMUY	Definitive	Altered Expression	[73]
HSD17B1	TTIWB6L	Definitive	Altered Expression	[74]
JAK1	TT6DM01	Definitive	Genetic Variation	[75]
KLF4	TTTI53X	Definitive	Biomarker	[76]
LTB	TTHQ6US	Definitive	Altered Expression	[77]
LTBR	TTFO0PM	Definitive	Biomarker	[77]
PLP2	TTK5OG6	Definitive	Biomarker	[78]
RHO	TTH0KSX	Definitive	Altered Expression	[79]
RPL15	TTQRVC9	Definitive	Biomarker	[80]

This Disease Is Related to 4 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC5	DTYVM24	Limited	Biomarker	[81]
ABCA2	DTJ4NEG	Strong	Altered Expression	[82]
ABCA3	DT2T6VQ	Strong	Altered Expression	[82]
SLC7A7	DTE4HJ8	Strong	Biomarker	[83]

This Disease Is Related to 5 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
DHRS9	DEGTU5I	Limited	Biomarker	[84]
AKR1C1	DE7P2FB	Strong	Biomarker	[85]
ALDH1A2	DEKN1H4	Strong	Altered Expression	[86]
NT5C2	DE1DOKJ	Strong	Genetic Variation	[87]
SCLY	DEH4TD6	Strong	Biomarker	[88]

This Disease Is Related to 162 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ADD1	OTTF68DC	Limited	Genetic Variation	[89]
AFDN	OTTRU341	Limited	Genetic Variation	[90]
AFF2	OTMF1PZW	Limited	Genetic Variation	[91]
AFF3	OTR0705Z	Limited	Genetic Variation	[91]
CCDC28A	OTSWUMXT	Limited	Biomarker	[92]
CKS1B	OTNUPLUJ	Limited	Altered Expression	[93]
CKS2	OTPTMHIV	Limited	Altered Expression	[93]
CLDN10	OT2CVAKY	Limited	Biomarker	[94]
COL4A5	OTHG60RE	Limited	Altered Expression	[95]
EDIL3	OTDVVNS0	Limited	Genetic Variation	[96]
EML1	OTOP2E01	Limited	Biomarker	[97]
GLIS2	OTOUUV1X	Limited	Genetic Variation	[98]
GNLY	OTZJKA8C	Limited	Biomarker	[99]
HENMT1	OTM5I26B	Limited	Biomarker	[100]
HEY2	OTU4J3ZI	Limited	Biomarker	[101]
IARS1	OT9WXH5N	Limited	Altered Expression	[95]
IRS4	OTTOL40K	Limited	Altered Expression	[95]
LMO4	OT5NDCT9	Limited	Biomarker	[102]
LRSAM1	OTOKWR6C	Limited	Genetic Variation	[103]
MBD2	OTUQPP0R	Limited	Biomarker	[104]
MLLT1	OT41UZU5	Limited	Altered Expression	[105]
MPST	OTCDPH5D	Limited	Biomarker	[11]
MSTO1	OT37XCNP	Limited	Biomarker	[11]
MSX2	OT1WDKE1	Limited	Altered Expression	[106]
NHLH1	OTXN5B9R	Limited	Biomarker	[100]
PBX2	OTEBYCAW	Limited	Altered Expression	[107]
PDIK1L	OTISF4KG	Limited	Biomarker	[108]
PITX1	OTA0UN4C	Limited	Altered Expression	[109]
POGLUT1	OTDX7GZD	Limited	Altered Expression	[110]
POLD4	OTG578YH	Limited	Altered Expression	[111]
POLE4	OTCMWUT6	Limited	Altered Expression	[111]
RMC1	OT7K8MTJ	Limited	Genetic Variation	[112]
SETBP1	OTKGCOSR	Limited	Genetic Variation	[113]
SIX6	OTD1RD9D	Limited	Altered Expression	[14]
TALDO1	OTDKV2S2	Limited	Genetic Variation	[103]
TCHP	OTVDMHSY	Limited	Biomarker	[114]
TFAP2C	OTUDIW05	Limited	Altered Expression	[14]
TPD52	OTPKSK43	Limited	Altered Expression	[115]
TSN	OTOFAQ2Z	Limited	Altered Expression	[116]
APIP	OT8ZABOU	Disputed	Biomarker	[25]
FAM133B	OTQH2A95	Disputed	Genetic Variation	[25]
NAP1L1	OTI7WBZV	Disputed	Biomarker	[117]
RASGRP4	OT15PWN4	Disputed	Biomarker	[118]
TAL2	OTSK1E88	Disputed	Biomarker	[119]
BCL10	OT47MCLI	moderate	Biomarker	[120]
CTCF	OT8ZB70U	moderate	Biomarker	[19]
DDX3X	OTDO4TRX	moderate	FusionGene	[117]
HNRNPH1	OTFRWOLM	moderate	FusionGene	[117]
SALL2	OTQWI68Q	moderate	FusionGene	[121]
ADD3	OTDRSHAZ	Strong	Biomarker	[113]
ARID5B	OTUQ4CQY	Strong	Genetic Variation	[88]
ASB2	OTF9LV7L	Strong	Altered Expression	[122]
ASPG	OT5E2EKR	Strong	Biomarker	[61]
BAALC	OTUZSRVF	Strong	Altered Expression	[123]
BCR	OTCN76C1	Strong	Genetic Variation	[124]
CCT4	OT5D452X	Strong	Biomarker	[42]
CD79A	OTOJC8DV	Strong	Altered Expression	[125]
CDKN2B	OTAG24N1	Strong	Genetic Variation	[126]
CERS6	OTOP4GV1	Strong	Biomarker	[127]
CNKSR3	OTXP4QH8	Strong	Altered Expression	[128]
DNASE1L3	OTEUIMC2	Strong	Biomarker	[129]
ETV6	OTCZMG61	Strong	Genetic Variation	[61]
FANCB	OTMZTXB5	Strong	Genetic Variation	[130]
FANCD2	OTVEB5LF	Strong	Genetic Variation	[131]
FOXN1	OTE80D6I	Strong	Genetic Variation	[132]
HHEX	OTLIUVYX	Strong	Biomarker	[133]
HOXA10	OTB6GQ09	Strong	Genetic Variation	[134]
HOXA9	OTKNK5H0	Strong	Altered Expression	[135]
IKZF1	OTCW1FKL	Strong	Biomarker	[35]
IRX3	OTLJ48FG	Strong	Altered Expression	[136]
JDP2	OTW35WKX	Strong	Biomarker	[137]
KDM6A	OTZM3MJJ	Strong	Biomarker	[138]
KRT7	OTLT3JFN	Strong	Biomarker	[88]
LDB1	OT20EAPR	Strong	Altered Expression	[133]
LHX2	OTK61NP8	Strong	Altered Expression	[133]
LYL1	OTCNOV1M	Strong	Biomarker	[139]
MAGI1	OTMV4ASV	Strong	Altered Expression	[128]
MAML1	OTQA4DDN	Strong	Biomarker	[66]
MATK	OTVOJJLJ	Strong	Altered Expression	[34]
MEF2C	OTZGF1Y5	Strong	Altered Expression	[140]
MLLT10	OTURMDV7	Strong	Biomarker	[141]
MRPL28	OT4LUTZU	Strong	Altered Expression	[142]
MSX1	OT5U41ZP	Strong	Biomarker	[143]
NEUROD1	OTZQ7QJ2	Strong	Biomarker	[144]
NFATC3	OTYOORME	Strong	Biomarker	[145]
NKX2-3	OTF4IL5J	Strong	Genetic Variation	[98]
NKX2-5	OTS1SAWM	Strong	Altered Expression	[146]
NKX3-2	OTH4NRH7	Strong	Altered Expression	[147]
NR2E1	OTW47GKM	Strong	Biomarker	[33]
NRARP	OTMYHUV2	Strong	Biomarker	[148]
NUP98	OTNT12G2	Strong	Altered Expression	[139]
NXT1	OT0VO6AY	Strong	Altered Expression	[142]
OLIG2	OTMCN6D3	Strong	Altered Expression	[149]
PICALM	OTQVRPMQ	Strong	Biomarker	[150]
PLEKHG2	OTMGR6I6	Strong	Biomarker	[151]
PMAIP1	OTXEE550	Strong	Altered Expression	[34]
PRDM14	OTWZKY4L	Strong	Biomarker	[152]
PRDM16	OT0BGA27	Strong	Altered Expression	[153]
RAG2	OTG9UYTW	Strong	Biomarker	[154]
RASGRP1	OTX9WN2E	Strong	Altered Expression	[155]
RBBP8	OTRHJ3GI	Strong	Biomarker	[53]
RPL10	OTBHOZGC	Strong	Genetic Variation	[156]
RPL5	OTM8EBRI	Strong	Biomarker	[157]
RPS15	OT0WYZYG	Strong	Genetic Variation	[156]
SET	OTGYYQJO	Strong	FusionGene	[121]
SHQ1	OTFBXX2H	Strong	Biomarker	[158]
SOCS5	OTN1ABYR	Strong	Posttranslational Modification	[159]
SOS1	OTTCWXC3	Strong	Biomarker	[160]
SPI1	OTVCA1D0	Strong	Biomarker	[161]
ST6GAL1	OT7US3NO	Strong	Biomarker	[162]
STAT5A	OTBSJGN3	Strong	Biomarker	[24]
STAT5B	OTZVPEBT	Strong	Biomarker	[24]
STIL	OT9799VN	Strong	Biomarker	[163]
STIM2	OTYNXAW0	Strong	Biomarker	[164]
SUZ12	OT655XF8	Strong	Altered Expression	[48]
TAF1	OTDYS5G4	Strong	Genetic Variation	[165]
TCF7	OT1ID822	Strong	Altered Expression	[166]
TCOF1	OT4BOYTM	Strong	Biomarker	[167]
THAP1	OTIWUSON	Strong	Biomarker	[40]
TIMM8A	OTDX9687	Strong	Genetic Variation	[16]
TLE1	OT50MRZ1	Strong	Altered Expression	[168]
TMEM102	OTXTYWXJ	Strong	Biomarker	[169]
TMEM132D	OTV6I4Z0	Strong	Biomarker	[69]
TRAF5	OTSBTLO0	Strong	Biomarker	[170]
ATF7IP	OTU6ZA7F	Definitive	Biomarker	[171]
AUTS2	OTAEXHSC	Definitive	Altered Expression	[172]
AVEN	OTGIN5YK	Definitive	Altered Expression	[173]
CALM2	OTNYA92F	Definitive	Biomarker	[150]
CARD11	OTRCTLYC	Definitive	Altered Expression	[120]
CBFB	OTIAC6W4	Definitive	Biomarker	[174]
CCAR1	OTUXLQZZ	Definitive	Biomarker	[175]
CCL25	OTLWJ8CJ	Definitive	Biomarker	[176]
CCNC	OTMVK4K4	Definitive	Genetic Variation	[177]
CLTC	OTBFASMA	Definitive	Biomarker	[25]
DNTT	OTFSEF12	Definitive	Biomarker	[178]
EFL1	OTMEXJZA	Definitive	Genetic Variation	[80]
EIF4A1	OTMTBX6N	Definitive	Biomarker	[179]
EIF4A2	OT08H03R	Definitive	Biomarker	[179]
FEM1B	OTFE2ELA	Definitive	Altered Expression	[180]
GFER	OTVK43OK	Definitive	Biomarker	[181]
GNL3	OTILGYO4	Definitive	Biomarker	[182]
MAFB	OTH2N3T8	Definitive	Altered Expression	[183]
MAML2	OT1TSVAR	Definitive	Genetic Variation	[184]
MCU	OTQZAYWQ	Definitive	Biomarker	[185]
MEIS1	OTH9DKAD	Definitive	Altered Expression	[186]
NFKBIE	OTLAYEL9	Definitive	Genetic Variation	[187]
NMD3	OTXC5APO	Definitive	Genetic Variation	[80]
NUP155	OTIIAH4E	Definitive	Biomarker	[188]
PANX1	OTXPEDOK	Definitive	Biomarker	[189]
PDLIM5	OTLQVV22	Definitive	Altered Expression	[190]
PTPRU	OTHDO0QG	Definitive	Genetic Variation	[191]
RAP1GDS1	OTH70UHD	Definitive	Biomarker	[192]
RASA2	OTL06RG2	Definitive	Biomarker	[193]
RPL22	OTVCN8K0	Definitive	Biomarker	[194]
SCD5	OTSSUQ3Z	Definitive	Altered Expression	[70]
SEMA3F	OTQFMS8S	Definitive	Altered Expression	[195]
SLC2A4RG	OTW3LX8D	Definitive	Biomarker	[196]
SMC4	OTEJE6AG	Definitive	Biomarker	[188]
SNAP91	OTE3EXWZ	Definitive	Biomarker	[150]
TAPBP	OTL81AVZ	Definitive	Biomarker	[197]
TCL1B	OT4CSO39	Definitive	Genetic Variation	[63]
TOX	OTE8BL5Z	Definitive	Biomarker	[198]

References

• [1] Nelarabine FDA Label
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Identification of an ETV6-ABL2 fusion transcript in combination with an ETV6 point mutation in a T-cell acute lymphoblastic leukaemia cell line.Br J Haematol. 2002 Nov;119(2):454-8. doi: 10.1046/j.1365-2141.2002.03850.x.
• [4] 11;14 translocation in childhood T-cell acute lymphoblastic leukemia.Jpn J Cancer Res. 1985 Mar;76(3):160-1.
• [5] T cell receptor-CD3 complex during early T cell differentiation. Analysis of immature T cell acute lymphoblastic leukemias (T-ALL) at DNA, RNA, and cell membrane level.J Immunol. 1987 Feb 15;138(4):1260-9.
• [6] The COOH terminus of p18INK4C distinguishes function from p16INK4A.Cancer Res. 2001 May 15;61(10):3863-8.
• [7] T cell receptor alpha-chain gene rearrangements in B-precursor leukemia are in contrast to the findings in T cell acute lymphoblastic leukemia. Comparative study of T cell receptor gene rearrangement in childhood leukemia.J Clin Invest. 1987 Dec;80(6):1770-7. doi: 10.1172/JCI113270.
• [8] A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias.Leukemia. 2005 Mar;19(3):358-66. doi: 10.1038/sj.leu.2403657.
• [9] Transforming potential of the T-cell acute lymphoblastic leukemia-associated homeobox genes HOXA13, TLX1, and TLX3.Genes Chromosomes Cancer. 2006 Sep;45(9):846-55. doi: 10.1002/gcc.20348.
• [10] Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.Blood. 2017 Dec 21;130(25):2750-2761. doi: 10.1182/blood-2017-05-784603. Epub 2017 Nov 3.
• [11] Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia.Genes Chromosomes Cancer. 2005 Jan;42(1):87-94. doi: 10.1002/gcc.20116.
• [12] Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update.Int J Mol Sci. 2018 Jun 26;19(7):1878. doi: 10.3390/ijms19071878.
• [13] Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies.Leukemia. 2008 Jun;22(6):1117-24. doi: 10.1038/leu.2008.80. Epub 2008 Apr 10.
• [14] HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL).Blood. 2005 Jul 1;106(1):274-86. doi: 10.1182/blood-2004-10-3900. Epub 2005 Mar 17.
• [15] Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias.Exp Hematol. 2011 Feb;39(2):195-202.e2. doi: 10.1016/j.exphem.2010.10.008. Epub 2010 Nov 4.
• [16] Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia.Blood. 1998 Feb 1;91(3):1016-20.
• [17] State of chromosome 11q23 in T-ALL/LBL and their relation to prognosis.Appl Immunohistochem Mol Morphol. 2012 Jul;20(4):375-80. doi: 10.1097/PAI.0b013e31822d1198.
• [18] Frequent microsatellite instability and BAX mutations in T cell acute lymphoblastic leukemia cell lines.Leuk Res. 2000 Mar;24(3):255-62. doi: 10.1016/s0145-2126(99)00182-4.
• [19] The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.Nat Genet. 2017 Aug;49(8):1211-1218. doi: 10.1038/ng.3909. Epub 2017 Jul 3.
• [20] Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia. 2009 Dec;11(12):1359-70. doi: 10.1593/neo.91314.
• [21] ARRB1-Promoted NOTCH1 Degradation Is Suppressed by OncomiR miR-223 in T-cell Acute Lymphoblastic Leukemia.Cancer Res. 2020 Mar 1;80(5):988-998. doi: 10.1158/0008-5472.CAN-19-1471. Epub 2019 Dec 10.
• [22] Synergistic Cytotoxic Effect of L-Asparaginase Combined with Decitabine as a Demethylating Agent in Pediatric T-ALL, with Specific Epigenetic Signature.Biomed Res Int. 2016;2016:1985750. doi: 10.1155/2016/1985750. Epub 2016 Nov 27.
• [23] Anti-leukaemic activity of the TYK2 selective inhibitor NDI-031301 in T-cell acute lymphoblastic leukaemia.Br J Haematol. 2017 Apr;177(2):271-282. doi: 10.1111/bjh.14563. Epub 2017 Mar 14.
• [24] Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes.J Clin Invest. 2020 Feb 3;130(2):863-876. doi: 10.1172/JCI130189.
• [25] Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.PLoS Genet. 2013 Apr;9(4):e1003464. doi: 10.1371/journal.pgen.1003464. Epub 2013 Apr 25.
• [26] Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.Clin Cancer Res. 2017 Feb 15;23(4):1012-1024. doi: 10.1158/1078-0432.CCR-15-2869. Epub 2016 Nov 9.
• [27] 92R Monoclonal Antibody Inhibits Human CCR9(+) Leukemia Cells Growth in NSG Mice Xenografts.Front Immunol. 2018 Jan 29;9:77. doi: 10.3389/fimmu.2018.00077. eCollection 2018.
• [28] Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.Blood. 2019 May 23;133(21):2291-2304. doi: 10.1182/blood-2018-10-882944. Epub 2019 Feb 22.
• [29] Therapy of Philadelphia chromosome-negative acute lymphoblastic leukemia in adults: new paradigms.Future Oncol. 2009 Sep;5(7):1039-50. doi: 10.2217/fon.09.74.
• [30] BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia.Leukemia. 2010 Aug;24(8):1429-36. doi: 10.1038/leu.2010.130. Epub 2010 Jun 10.
• [31] Speed of leukemia development and genetic diversity in xenograft models of T cell acute lymphoblastic leukemia.Oncotarget. 2016 Jul 5;7(27):41599-41611. doi: 10.18632/oncotarget.9313.
• [32] Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.Blood. 2018 Mar 1;131(9):995-999. doi: 10.1182/blood-2017-07-794214. Epub 2018 Jan 5.
• [33] IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.PLoS Med. 2016 Dec 20;13(12):e1002200. doi: 10.1371/journal.pmed.1002200. eCollection 2016 Dec.
• [34] Enhancement of Quercetin-Induced Apoptosis by Cotreatment with Autophagy Inhibitor Is Associated with Augmentation of BAK-Dependent Mitochondrial Pathway in Jurkat T Cells.Oxid Med Cell Longev. 2019 Nov 15;2019:7989276. doi: 10.1155/2019/7989276. eCollection 2019.
• [35] CRLF2 expression associates with ICN1 stabilization in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2019 Jun;58(6):396-401.
• [36] Ghrelin induces autophagy and CXCR4 expression via the SIRT1/AMPK axis in lymphoblastic leukemia cell lines.Cell Signal. 2020 Feb;66:109492. doi: 10.1016/j.cellsig.2019.109492. Epub 2019 Dec 3.
• [37] T-cell receptor gamma and delta gene rearrangements and junctional region characteristics in south Indian patients with T-cell acute lymphoblastic leukemia.Am J Hematol. 2007 Mar;82(3):215-21. doi: 10.1002/ajh.20792.
• [38] DLL4 regulates NOTCH signaling and growth of T acute lymphoblastic leukemia cells in NOD/SCID mice.Carcinogenesis. 2015 Jan;36(1):115-21. doi: 10.1093/carcin/bgu223. Epub 2014 Oct 29.
• [39] Targeting High Dynamin-2 (DNM2) Expression by Restoring Ikaros Function in Acute Lymphoblastic Leukemia.Sci Rep. 2016 Nov 25;6:38004. doi: 10.1038/srep38004.
• [40] A novel long non-coding RNA T-ALL-R-LncR1 knockdown and Par-4 cooperate to induce cellular apoptosis in T-cell acute lymphoblastic leukemia cells.Leuk Lymphoma. 2014 Jun;55(6):1373-82. doi: 10.3109/10428194.2013.829574. Epub 2013 Aug 28.
• [41] Cell competition is a tumour suppressor mechanism in the thymus.Nature. 2014 May 22;509(7501):465-70. doi: 10.1038/nature13317. Epub 2014 May 14.
• [42] Repositioning of Difluorinated Propanediones as Inhibitors of Histone Methyltransferases and their Biological Evaluation in Human Leukemic Cell Lines.Anticancer Agents Med Chem. 2018;18(13):1892-1899. doi: 10.2174/1871520618666180404125721.
• [43] An integrated transcriptome analysis in T-cell acute lymphoblastic leukemia links DNA methylation subgroups to dysregulated TAL1 and ANTP homeobox gene expression.Cancer Med. 2019 Jan;8(1):311-324. doi: 10.1002/cam4.1917. Epub 2018 Dec 21.
• [44] Upregulation of AIOLOS induces apoptosis and enhances etoposide chemosensitivity in Jurkat leukemia cells.Oncol Rep. 2015 Mar;33(3):1319-25. doi: 10.3892/or.2014.3677. Epub 2014 Dec 18.
• [45] CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.Haematologica. 2019 Apr;104(4):749-755. doi: 10.3324/haematol.2018.205252. Epub 2018 Oct 25.
• [46] New anti-IL-7R monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models.Leukemia. 2020 Jan;34(1):35-49. doi: 10.1038/s41375-019-0531-8. Epub 2019 Aug 22.
• [47] Erratum: Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia [Corrigendum].Int J Nanomedicine. 2018 Jan 31;13:615. doi: 10.2147/IJN.S162136. eCollection 2018.
• [48] Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.Blood. 2019 Oct 17;134(16):1323-1336. doi: 10.1182/blood.2019000015.
• [49] Histone Modifications Drive Aberrant Notch3 Expression/Activity and Growth in T-ALL.Front Oncol. 2019 Apr 3;9:198. doi: 10.3389/fonc.2019.00198. eCollection 2019.
• [50] Mouse acute leukemia develops independent of self-renewal and differentiation potentials in hematopoietic stem and progenitor cells.Blood Adv. 2019 Feb 12;3(3):419-431. doi: 10.1182/bloodadvances.2018022400.
• [51] Cellular proteolytic modification of tumor-suppressor CYLD is critical for the initiation of human T-cell acute lymphoblastic leukemia.Blood Cells Mol Dis. 2015 Jan;54(1):132-8. doi: 10.1016/j.bcmd.2014.07.008. Epub 2014 Aug 12.
• [52] Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination.Cancer Chemother Pharmacol. 2015 Jun;75(6):1247-52. doi: 10.1007/s00280-015-2747-2. Epub 2015 Apr 28.
• [53] Regulatory network analysis reveals the oncogenesis roles of feed-forward loops and therapeutic target in T-cell acute lymphoblastic leukemia.BMC Med Genomics. 2019 Jan 15;12(1):8. doi: 10.1186/s12920-018-0469-0.
• [54] Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically heterogeneous mouse model of T-cell acute lymphoblastic leukemia.Dis Model Mech. 2019 Sep 16;12(9):dmm040931. doi: 10.1242/dmm.040931.
• [55] Epigenetic regulation of PAX5 expression in acute T-cell lymphoblastic leukemia.Leuk Res. 2011 May;35(5):614-9. doi: 10.1016/j.leukres.2010.11.015. Epub 2010 Dec 14.
• [56] The clinical significance of monitoring the expression of the SIL-TAL1 fusion gene in T-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.Int J Lab Hematol. 2017 Dec;39(6):613-619. doi: 10.1111/ijlh.12711. Epub 2017 Jul 24.
• [57] CD3D and PRKCQ work together to discriminate between B-cell and T-cell acute lymphoblastic leukemia.Comput Biol Med. 2016 Oct 1;77:16-22. doi: 10.1016/j.compbiomed.2016.07.004. Epub 2016 Jul 11.
• [58] Aptamer-targeted DNA nanostructures with doxorubicin to treat protein tyrosine kinase 7-positive tumours.Cell Prolif. 2019 Jan;52(1):e12511. doi: 10.1111/cpr.12511. Epub 2018 Oct 12.
• [59] Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia.Blood Adv. 2019 Jul 9;3(13):1981-1988. doi: 10.1182/bloodadvances.2018028993.
• [60] Extension of the Notch intracellular domain ankyrin repeat stack by NRARP promotes feedback inhibition of Notch signaling.Sci Signal. 2019 Nov 5;12(606):eaay2369. doi: 10.1126/scisignal.aay2369.
• [61] Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia.Lancet Oncol. 2019 Mar;20(3):e142-e154. doi: 10.1016/S1470-2045(19)30031-2.
• [62] TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.Cancer Discov. 2013 May;3(5):564-77. doi: 10.1158/2159-8290.CD-12-0504. Epub 2013 Mar 7.
• [63] Tcr translocations that delete the Bcl11b haploinsufficient tumor suppressor gene promote atm-deficient T cell acute lymphoblastic leukemia.Cell Cycle. 2014;13(19):3076-82. doi: 10.4161/15384101.2014.949144.
• [64] Impact of microRNA-29b on natural killer cells in T-cell acute lymphoblastic leukemia.Oncol Lett. 2019 Sep;18(3):2394-2403. doi: 10.3892/ol.2019.10559. Epub 2019 Jul 4.
• [65] A novel TRB@/NOTCH1 fusion gene in T-cell lymphoblastic lymphoma with t(7;9)(q34;q34).Eur J Haematol. 2013 Jan;90(1):68-75. doi: 10.1111/ejh.12019. Epub 2012 Nov 29.
• [66] Knockdown of MAML1 inhibits proliferation and induces apoptosis of T-cell acute lymphoblastic leukemia cells through SP1-dependent inactivation of TRIM59.J Cell Physiol. 2019 Apr;234(4):5186-5195. doi: 10.1002/jcp.27323. Epub 2018 Oct 28.
• [67] USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia.Clin Cancer Res. 2019 Jan 1;25(1):222-239. doi: 10.1158/1078-0432.CCR-18-1740. Epub 2018 Sep 17.
• [68] Pharmacological inhibition of carbonic anhydrase XII interferes with cell proliferation and induces cell apoptosis in T-cell lymphomas.Cancer Lett. 2013 Jun 1;333(1):76-88. doi: 10.1016/j.canlet.2013.01.020. Epub 2013 Jan 21.
• [69] CD47 agonist peptide PKHB1 induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells.Cancer Sci. 2019 Jan;110(1):256-268. doi: 10.1111/cas.13885. Epub 2018 Dec 14.
• [70] Exonal switch down-regulates the expression of CD5 on blasts of acute T cell leukaemia.Clin Exp Immunol. 2017 Dec;190(3):340-350. doi: 10.1111/cei.13019. Epub 2017 Sep 5.
• [71] The epigenetic factor BORIS/CTCFL regulates the NOTCH3 gene expression in cancer cells.Biochim Biophys Acta. 2014 Sep;1839(9):813-25. doi: 10.1016/j.bbagrm.2014.06.017. Epub 2014 Jun 28.
• [72] DEPTOR is a direct NOTCH1 target that promotes cell proliferation and survival in T-cell leukemia.Oncogene. 2017 Feb 23;36(8):1038-1047. doi: 10.1038/onc.2016.275. Epub 2016 Sep 5.
• [73] The EphB6 receptor is overexpressed in pediatric T cell acute lymphoblastic leukemia and increases its sensitivity to doxorubicin treatment.Sci Rep. 2017 Nov 7;7(1):14767. doi: 10.1038/s41598-017-15200-3.
• [74] Conversion of estrone to 17 beta-estradiol in Jurkat acute T cell leukemia Hut-78 T- and Raji B lymphoma cell lines in vitro.Biomed Pharmacother. 2013 May;67(4):299-303. doi: 10.1016/j.biopha.2012.11.003. Epub 2012 Nov 20.
• [75] Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-R mutations.Oncotarget. 2018 Apr 27;9(32):22605-22617. doi: 10.18632/oncotarget.25194. eCollection 2018 Apr 27.
• [76] Concise Review: Regulation of Self-Renewal in Normal and Malignant Hematopoietic Stem Cells by Krppel-Like Factor 4.Stem Cells Transl Med. 2019 Jun;8(6):568-574. doi: 10.1002/sctm.18-0249. Epub 2019 Feb 21.
• [77] Lymphotoxin- receptor in microenvironmental cells promotes the development of T-cell acute lymphoblastic leukaemia with cortical/mature immunophenotype.Br J Haematol. 2015 Dec;171(5):736-51. doi: 10.1111/bjh.13760. Epub 2015 Oct 12.
• [78] miR-664 negatively regulates PLP2 and promotes cell proliferation and invasion in T-cell acute lymphoblastic leukaemia.Biochem Biophys Res Commun. 2015 Apr 3;459(2):340-345. doi: 10.1016/j.bbrc.2015.02.116. Epub 2015 Feb 28.
• [79] Analysis of Rho GTPase expression in T-ALL identifies RhoU as a target for Notch involved in T-ALL cell migration.Oncogene. 2013 Jan 10;32(2):198-208. doi: 10.1038/onc.2012.42. Epub 2012 Feb 20.
• [80] The T-cell leukemia related rpl10-R98S mutant traps the 60S export adapter Nmd3 in the ribosomal P site in yeast.PLoS Genet. 2017 Jul 17;13(7):e1006894. doi: 10.1371/journal.pgen.1006894. eCollection 2017 Jul.
• [81] The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype.Blood. 2003 Dec 15;102(13):4493-8. doi: 10.1182/blood-2002-11-3461. Epub 2003 Jun 19.
• [82] Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther. 2006 Aug;5(8):1986-94.
• [83] Function of SLC7A7 in T-Cell Acute Lymphoblastic Leukemia. Cell Physiol Biochem. 2018;48(2):731-740.
• [84] Biallelic deletion and loss of expression analysis of genes at FRA2G common fragile site in tumor-derived cell lines.Cancer Genet Cytogenet. 2005 Sep;161(2):181-6. doi: 10.1016/j.cancergencyto.2005.01.018.
• [85] AKR1C enzymes sustain therapy resistance in paediatric T-ALL.Br J Cancer. 2018 Apr;118(7):985-994. doi: 10.1038/s41416-018-0014-0. Epub 2018 Mar 8.
• [86] Aberrant expression of aldehyde dehydrogenase 1A (ALDH1A) subfamily genes in acute lymphoblastic leukaemia is a common feature of T-lineage tumours.Br J Haematol. 2015 Jan;168(2):246-57. doi: 10.1111/bjh.13120. Epub 2014 Sep 11.
• [87] Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia.Blood Cancer J. 2017 Feb 3;7(2):e523. doi: 10.1038/bcj.2017.3.
• [88] Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia.Leukemia. 2018 Oct;32(10):2138-2151. doi: 10.1038/s41375-018-0110-4. Epub 2018 Mar 26.
• [89] T-cell acute lymphoblastic leukemia with add(1)(p36) and del(12)(p11) following acute myelocytic leukemia with partial deletion of 9p.Cancer Genet Cytogenet. 2004 Apr 1;150(1):62-5. doi: 10.1016/j.cancergencyto.2003.08.003.
• [90] Analysis of the t(6;11)(q27;q23) in leukemia shows a consistent breakpoint in AF6 in three patients and in the ML-2 cell line.Genes Chromosomes Cancer. 1996 Apr;15(4):206-16. doi: 10.1002/(SICI)1098-2264(199604)15:4<206::AID-GCC2>3.0.CO;2-5.
• [91] Identification of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t(2;21)(q11;q22) by bubble PCR method for cDNA.Oncogene. 2008 Apr 3;27(15):2249-56. doi: 10.1038/sj.onc.1210857. Epub 2007 Oct 29.
• [92] NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogntique Hmatologique.Leukemia. 2006 Apr;20(4):696-706. doi: 10.1038/sj.leu.2404130.
• [93] ckshs expression is linked to cell proliferation in normal and malignant human lymphoid cells.Int J Cancer. 1999 Jul 2;82(1):98-104. doi: 10.1002/(sici)1097-0215(19990702)82:1<98::aid-ijc17>3.0.co;2-a.
• [94] T-cell acute lymphoblastic leukemia and the associated basic helix-loop-helix gene SCL/tal.Leuk Lymphoma. 1994 Jan;12(3-4):157-66. doi: 10.3109/10428199409059586.
• [95] The t(X;7)(q22;q34) in paediatric T-cell acute lymphoblastic leukaemia results in overexpression of the insulin receptor substrate 4 gene through illegitimate recombination with the T-cell receptor beta locus.Br J Haematol. 2009 Feb;144(4):546-51. doi: 10.1111/j.1365-2141.2008.07453.x. Epub 2008 Nov 13.
• [96] Development and validation of a quantitative polymerase chain reaction assay to evaluate minimal residual disease for T-cell acute lymphoblastic leukemia and follicular lymphoma.Am J Pathol. 1999 Apr;154(4):1023-35. doi: 10.1016/S0002-9440(10)65355-2.
• [97] Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).Blood. 2005 Jun 15;105(12):4849-52. doi: 10.1182/blood-2004-12-4897. Epub 2005 Feb 15.
• [98] TCR rearrangements identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome.Leukemia. 2018 Jan;32(1):61-71. doi: 10.1038/leu.2017.176. Epub 2017 Jun 8.
• [99] Notch/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression.Blood. 2011 Mar 10;117(10):2891-900. doi: 10.1182/blood-2009-12-253419. Epub 2011 Jan 11.
• [100] HEN1 and HEN2: a subgroup of basic helix-loop-helix genes that are coexpressed in a human neuroblastoma.Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8492-6. doi: 10.1073/pnas.89.18.8492.
• [101] Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines.Exp Cell Res. 2007 Aug 15;313(14):3141-52. doi: 10.1016/j.yexcr.2007.04.027. Epub 2007 May 5.
• [102] The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer.Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14452-7. doi: 10.1073/pnas.251547698.
• [103] Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia.Best Pract Res Clin Haematol. 2010 Sep;23(3):307-18. doi: 10.1016/j.beha.2010.08.002. Epub 2010 Oct 30.
• [104] MBD2 Ablation Impairs Lymphopoiesis and Impedes Progression and Maintenance of T-ALL.Cancer Res. 2018 Apr 1;78(7):1632-1642. doi: 10.1158/0008-5472.CAN-17-1434. Epub 2018 Jan 12.
• [105] Complex MLL rearrangement in a patient with T-cell acute lymphoblastic leukemia.Genes Chromosomes Cancer. 1995 Sep;14(1):76-84. doi: 10.1002/gcc.2870140114.
• [106] NK-like homeodomain proteins activate NOTCH3-signaling in leukemic T-cells.BMC Cancer. 2009 Oct 19;9:371. doi: 10.1186/1471-2407-9-371.
• [107] TALE homeoproteins as HOX11-interacting partners in T-cell leukemia.Leuk Lymphoma. 2000 Oct;39(3-4):241-56. doi: 10.3109/10428190009065824.
• [108] Synergistic therapeutic effect of diethylstilbestrol and CX-4945 in human acute T-lymphocytic leukemia cells.Biomed Pharmacother. 2018 Feb;98:357-363. doi: 10.1016/j.biopha.2017.12.078. Epub 2017 Dec 27.
• [109] Activation of Paired-homeobox gene PITX1 by del(5)(q31) in T-cell acute lymphoblastic leukemia.Leuk Lymphoma. 2011 Jul;52(7):1348-59. doi: 10.3109/10428194.2011.566391. Epub 2011 Mar 22.
• [110] Overexpression of human CAP10-like protein 46 KD in T-acute lymphoblastic leukemia and acute myelogenous leukemia.Genet Test Mol Biomarkers. 2010 Feb;14(1):127-33. doi: 10.1089/gtmb.2009.0145.
• [111] Multipoint interphase FISH in childhood T-acute lymphoblastic leukemia detects subpopulations that carry different chromosome 3 aberrations.Cancer Genet Cytogenet. 2007 Jan 1;172(1):54-60. doi: 10.1016/j.cancergencyto.2006.08.004.
• [112] A panel of irradiation-reduced hybrids selectively retaining human chromosome 11p13: their structure and use to purify the WAGR gene complex.Genomics. 1990 Jan;6(1):48-64. doi: 10.1016/0888-7543(90)90447-3.
• [113] Fusion of NUP98 and the SET binding protein 1 (SETBP1) gene in a paediatric acute T cell lymphoblastic leukaemia with t(11;18)(p15;q12).Br J Haematol. 2007 Jan;136(2):294-6. doi: 10.1111/j.1365-2141.2006.06410.x.
• [114] SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.Nature. 2011 Mar 3;471(7336):104-9. doi: 10.1038/nature09732.
• [115] Expression of tumor protein D52-like genes in childhood leukemia at diagnosis: clinical and sample considerations.Leuk Res. 2006 Nov;30(11):1355-63. doi: 10.1016/j.leukres.2006.03.009. Epub 2006 Apr 18.
• [116] Recombination hotspot associated factors specifically recognize novel target sequences at the site of interchromosomal rearrangements in T-ALL patients with t(8;14)(q24;q11) and t(1;14)(p32;q11).Int Immunol. 1994 Jul;6(7):1017-25. doi: 10.1093/intimm/6.7.1017.
• [117] New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia.Blood. 2013 Jun 20;121(25):5064-7. doi: 10.1182/blood-2013-02-487256. Epub 2013 May 14.
• [118] Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesis.Leukemia. 2012 May;26(5):1038-45. doi: 10.1038/leu.2011.328. Epub 2011 Nov 25.
• [119] V(D)J-mediated translocations in lymphoid neoplasms: a functional assessment of genomic instability by cryptic sites.J Exp Med. 2002 Jan 7;195(1):85-98. doi: 10.1084/jem.20011578.
• [120] Characteristics of CARMA1-BCL10-MALT1-A20-NF-B expression in T cell-acute lymphocytic leukemia.Eur J Med Res. 2014 Nov 11;19(1):62. doi: 10.1186/s40001-014-0062-8.
• [121] Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia.Proc Natl Acad Sci U S A. 2018 Jan 9;115(2):373-378. doi: 10.1073/pnas.1717125115. Epub 2017 Dec 26.
• [122] The notch pathway promotes NF-B activation through Asb2 in T cell acute lymphoblastic leukemia cells.Cell Mol Biol Lett. 2018 Aug 9;23:37. doi: 10.1186/s11658-018-0102-4. eCollection 2018.
• [123] High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia.Blood. 2010 May 6;115(18):3737-44. doi: 10.1182/blood-2009-09-241943. Epub 2010 Jan 11.
• [124] Multidisciplinary analysis of pediatric T-ALL: 9q34 gene fusions.Cancer Genet. 2019 Feb;231-232:1-13. doi: 10.1016/j.cancergen.2018.12.002. Epub 2018 Dec 12.
• [125] Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias.J Pathol. 2002 Jul;197(3):341-7. doi: 10.1002/path.1126.
• [126] CDKN2B downregulation and other genetic characteristics in T-acute lymphoblastic leukemia.Exp Mol Med. 2019 Jan 11;51(1):1-15. doi: 10.1038/s12276-018-0195-x.
• [127] Ceramide synthase-6 confers resistance to chemotherapy by binding to CD95/Fas in T-cell acute lymphoblastic leukemia.Cell Death Dis. 2018 Sep 11;9(9):925. doi: 10.1038/s41419-018-0964-4.
• [128] MAGI-1 expression is decreased in several types of human T-cell leukemia cell lines, including adult T-cell leukemia.Int J Hematol. 2018 Mar;107(3):337-344. doi: 10.1007/s12185-017-2359-1. Epub 2017 Oct 17.
• [129] Eradication of Central Nervous System Leukemia of T-Cell Origin with a Brain-Permeable LSD1 Inhibitor.Clin Cancer Res. 2019 Mar 1;25(5):1601-1611. doi: 10.1158/1078-0432.CCR-18-0919. Epub 2018 Dec 5.
• [130] Childhood T-cell acute lymphoblastic leukemia with four distinct immunophenotypes representing different stages of T-cell development.Pediatr Hematol Oncol. 2001 Jun;18(4):267-72. doi: 10.1080/088800101750238577.
• [131] Heterozygote FANCD2 mutations associated with childhood T Cell ALL and testicular seminoma.Fam Cancer. 2012 Dec;11(4):661-5. doi: 10.1007/s10689-012-9553-3.
• [132] FoxN1-dependent thymic epithelial cells promote T-cell leukemia development.Carcinogenesis. 2018 Dec 31;39(12):1463-1476. doi: 10.1093/carcin/bgy127.
• [133] Overexpression of Lhx2 suppresses proliferation of human T cell acute lymphoblastic leukemia-derived cells, partly by reducing LMO2 protein levels.Biochem Biophys Res Commun. 2018 Jan 15;495(3):2310-2316. doi: 10.1016/j.bbrc.2017.12.135. Epub 2017 Dec 24.
• [134] Clinical, cytogenetic and molecular characteristics of 14 T-ALL patients carrying the TCRbeta-HOXA rearrangement: a study of the Groupe Francophone de Cytogntique Hmatologique.Leukemia. 2007 Jan;21(1):121-8. doi: 10.1038/sj.leu.2404410. Epub 2006 Oct 12.
• [135] HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.Cancer Discov. 2018 May;8(5):616-631. doi: 10.1158/2159-8290.CD-17-0583. Epub 2018 Mar 1.
• [136] Derepression of the Iroquois Homeodomain Transcription Factor Gene IRX3 Confers Differentiation Block in Acute Leukemia.Cell Rep. 2018 Jan 16;22(3):638-652. doi: 10.1016/j.celrep.2017.12.063.
• [137] JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia.J Exp Med. 2018 Jul 2;215(7):1929-1945. doi: 10.1084/jem.20170484. Epub 2018 Jun 25.
• [138] UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia.Genes Dev. 2016 Mar 1;30(5):508-21. doi: 10.1101/gad.276790.115.
• [139] The NUP98-HOXD13 fusion oncogene induces thymocyte self-renewal via Lmo2/Lyl1.Leukemia. 2019 Aug;33(8):1868-1880. doi: 10.1038/s41375-018-0361-0. Epub 2019 Jan 30.
• [140] MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.Leuk Lymphoma. 2017 Dec;58(12):2895-2904. doi: 10.1080/10428194.2017.1312383. Epub 2017 May 9.
• [141] CCAAT/enhancer-binding protein alpha (CEBPA) gene haploinsufficiency does not alter hematopoiesis or induce leukemia in Lck-CALM/AF10 transgenic mice.Braz J Med Biol Res. 2019;52(6):e8424. doi: 10.1590/1414-431X20198424. Epub 2019 May 27.
• [142] Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia.Clin Cancer Res. 2000 Apr;6(4):1219-28.
• [143] NKL homeobox gene activities in hematopoietic stem cells, T-cell development and T-cell leukemia.PLoS One. 2017 Feb 2;12(2):e0171164. doi: 10.1371/journal.pone.0171164. eCollection 2017.
• [144] Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia. Leukemia. 2005 Nov;19(11):1941-7. doi: 10.1038/sj.leu.2403836.
• [145] Novel Intergenically Spliced Chimera, NFATC3-PLA2G15, Is Associated with Aggressive T-ALL Biology and Outcome.Mol Cancer Res. 2018 Mar;16(3):470-475. doi: 10.1158/1541-7786.MCR-17-0442. Epub 2018 Jan 12.
• [146] Transcriptional deregulation of oncogenic myocyte enhancer factor 2C in T-cell acute lymphoblastic leukemia.Leuk Lymphoma. 2011 Feb;52(2):290-7. doi: 10.3109/10428194.2010.537003. Epub 2011 Jan 24.
• [147] Aberrant activity of NKL homeobox gene NKX3-2 in a T-ALL subset.PLoS One. 2018 May 10;13(5):e0197194. doi: 10.1371/journal.pone.0197194. eCollection 2018.
• [148] NRARP displays either pro- or anti-tumoral roles in T-cell acute lymphoblastic leukemia depending on Notch and Wnt signaling.Oncogene. 2020 Jan;39(5):975-986. doi: 10.1038/s41388-019-1042-9. Epub 2019 Oct 4.
• [149] OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1.Cancer Res. 2005 Aug 15;65(16):7151-8. doi: 10.1158/0008-5472.CAN-05-1400.
• [150] The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest.Haematologica. 2013 Nov;98(11):1711-7. doi: 10.3324/haematol.2013.086082. Epub 2013 Jul 5.
• [151] Results of successive EORTC-CLG 58881 and 58951 trials in paediatric T-cell acute lymphoblastic leukaemia (ALL).Br J Haematol. 2019 Sep;186(5):741-753. doi: 10.1111/bjh.15983. Epub 2019 May 24.
• [152] The Pluripotency Regulator PRDM14 Requires Hematopoietic Regulator CBFA2T3 to Initiate Leukemia in Mice.Mol Cancer Res. 2019 Jul;17(7):1468-1479. doi: 10.1158/1541-7786.MCR-18-1327. Epub 2019 Apr 23.
• [153] PRDM16 isoforms differentially regulate normal and leukemic hematopoiesis and inflammatory gene signature.J Clin Invest. 2018 Aug 1;128(8):3250-3264. doi: 10.1172/JCI99862. Epub 2018 Jul 23.
• [154] IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias.Cancer Res. 2011 Jul 15;71(14):4780-9. doi: 10.1158/0008-5472.CAN-10-3606. Epub 2011 May 18.
• [155] Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.PLoS One. 2018 May 25;13(5):e0193849. doi: 10.1371/journal.pone.0193849. eCollection 2018.
• [156] Ribosomal Lesions Promote Oncogenic Mutagenesis.Cancer Res. 2019 Jan 15;79(2):320-327. doi: 10.1158/0008-5472.CAN-18-1987. Epub 2018 Nov 27.
• [157] Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia.Nat Genet. 2013 Feb;45(2):186-90. doi: 10.1038/ng.2508. Epub 2012 Dec 23.
• [158] SHQ1 regulation of RNA splicing is required for T-lymphoblastic leukemia cell survival.Nat Commun. 2018 Oct 15;9(1):4281. doi: 10.1038/s41467-018-06523-4.
• [159] Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia.Cancer Sci. 2019 Jun;110(6):1931-1946. doi: 10.1111/cas.14021. Epub 2019 May 3.
• [160] Comprehensive Investigation of miRNome Identifies Novel Candidate miRNA-mRNA Interactions Implicated in T-Cell Acute Lymphoblastic Leukemia.Neoplasia. 2019 Mar;21(3):294-310. doi: 10.1016/j.neo.2019.01.004. Epub 2019 Feb 11.
• [161] Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia.Nat Genet. 2017 Aug;49(8):1274-1281. doi: 10.1038/ng.3900. Epub 2017 Jul 3.
• [162] Correction to: The regulatory ZFAS1/miR-150/ST6GAL1 crosstalk modulates sialylation of EGFR via PI3K/Akt pathway in T-cell acute lymphoblastic leukemia.J Exp Clin Cancer Res. 2019 Aug 16;38(1):357. doi: 10.1186/s13046-019-1365-y.
• [163] Origins of STIL-TAL1 fusion genes in children who later developed paediatric T-cell acute lymphoblastic leukaemia: An investigation of neonatal blood spots.Pediatr Blood Cancer. 2018 Nov;65(11):e27310. doi: 10.1002/pbc.27310. Epub 2018 Jul 3.
• [164] STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia.Cell Rep. 2018 Sep 11;24(11):3045-3060.e5. doi: 10.1016/j.celrep.2018.08.030.
• [165] SET-NUP214 is a recurrent lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL.Blood. 2014 Mar 20;123(12):1860-3. doi: 10.1182/blood-2013-08-521518. Epub 2014 Jan 21.
• [166] The TCF-1 and LEF-1 transcription factors have cooperative and opposing roles in T cell development and malignancy.Immunity. 2012 Nov 16;37(5):813-26. doi: 10.1016/j.immuni.2012.08.009. Epub 2012 Oct 25.
• [167] Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia.Blood. 1991 Apr 1;77(7):1546-54.
• [168] TLE1 as an indicator of adverse prognosis in pediatric acute lymphoblastic leukemia.Leuk Res. 2018 Nov;74:42-46. doi: 10.1016/j.leukres.2018.09.010. Epub 2018 Sep 26.
• [169] CBAP modulates Akt-dependent TSC2 phosphorylation to promote Rheb-mTORC1 signaling and growth of T-cell acute lymphoblastic leukemia.Oncogene. 2019 Feb;38(9):1432-1447. doi: 10.1038/s41388-018-0507-6. Epub 2018 Sep 28.
• [170] miR-141-3p and TRAF5 Network Contributes to the Progression of T-Cell Acute Lymphoblastic Leukemia.Cell Transplant. 2019 Dec;28(1_suppl):59S-65S. doi: 10.1177/0963689719887370. Epub 2019 Nov 14.
• [171] Development of neurologic diseases in a patient with primate T lymphotropic virus type 1 (PTLV-1).Retrovirology. 2016 Aug 12;13(1):56. doi: 10.1186/s12977-016-0290-9.
• [172] NKL homeobox gene MSX1 acts like a tumor suppressor in NK-cell leukemia.Oncotarget. 2017 Jun 21;8(40):66815-66832. doi: 10.18632/oncotarget.18609. eCollection 2017 Sep 15.
• [173] Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms.Oncogene. 2013 May 16;32(20):2586-91. doi: 10.1038/onc.2012.263. Epub 2012 Jul 2.
• [174] RUNX1 is required for oncogenic Myb and Myc enhancer activity in T-cell acute lymphoblastic leukemia.Blood. 2017 Oct 12;130(15):1722-1733. doi: 10.1182/blood-2017-03-775536. Epub 2017 Aug 8.
• [175] Par-4/THAP1 complex and Notch3 competitively regulated pre-mRNA splicing of CCAR1 and affected inversely the survival of T-cell acute lymphoblastic leukemia cells.Oncogene. 2013 Dec 12;32(50):5602-13. doi: 10.1038/onc.2013.349. Epub 2013 Aug 26.
• [176] NHE1 has a notable role in metastasis and drug resistance of T-cell acute lymphoblastic leukemia.Oncol Lett. 2017 Oct;14(4):4256-4262. doi: 10.3892/ol.2017.6716. Epub 2017 Aug 3.
• [177] Cyclin C is a haploinsufficient tumour suppressor.Nat Cell Biol. 2014 Nov;16(11):1080-91. doi: 10.1038/ncb3046. Epub 2014 Oct 26.
• [178] Protein signaling and regulation of gene transcription in leukemia: role of the Casein Kinase II-Ikaros axis.J Investig Med. 2016 Mar;64(3):735-9. doi: 10.1136/jim-2016-000075. Epub 2016 Feb 9.
• [179] RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer.Nature. 2014 Sep 4;513(7516):65-70. doi: 10.1038/nature13485. Epub 2014 Jul 27.
• [180] Increased PKC activity by Rack1 overexpression is responsible for chemotherapy resistance in T-cell acute lymphoblastic leukemia-derived cell line.Sci Rep. 2016 Sep 20;6:33717. doi: 10.1038/srep33717.
• [181] Decreased expression of the augmenter of liver regeneration results in growth inhibition and increased chemosensitivity of acute T lymphoblastic leukemia cells.Oncol Rep. 2017 Nov;38(5):3130-3136. doi: 10.3892/or.2017.5984. Epub 2017 Sep 21.
• [182] Nucleostemin knocking-down causes cell cycle arrest and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells via p53 and p21Waf1/Cip1 up-regulation.Hematology. 2014 Dec;19(8):455-62. doi: 10.1179/1607845414Y.0000000153. Epub 2014 Mar 17.
• [183] MAFB enhances oncogenic Notch signaling in T cell acute lymphoblastic leukemia.Sci Signal. 2017 Nov 14;10(505):eaam6846. doi: 10.1126/scisignal.aam6846.
• [184] First case of B ALL with KMT2A-MAML2 rearrangement: a case report.BMC Cancer. 2017 May 23;17(1):363. doi: 10.1186/s12885-017-3368-4.
• [185] Epstein-Barr Virus-associated Mucocutaneous Ulcer in a Patient With T-Cell Acute Lymphoblastic Leukemia: Importance of Accurate Diagnosis and Conservative Management.J Pediatr Hematol Oncol. 2017 Aug;39(6):e338-e341. doi: 10.1097/MPH.0000000000000709.
• [186] HOXA9 and MEIS1 gene overexpression in the diagnosis of childhood acute leukemias: Significant correlation with relapse and overall survival.Leuk Res. 2015 Aug;39(8):874-82. doi: 10.1016/j.leukres.2015.04.012. Epub 2015 Apr 27.
• [187] Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.Blood. 2016 Dec 8;128(23):2666-2670. doi: 10.1182/blood-2016-03-704528. Epub 2016 Sep 26.
• [188] NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.Haematologica. 2014 Jan;99(1):85-93. doi: 10.3324/haematol.2013.088674. Epub 2013 Jul 19.
• [189] Chemotherapeutic drugs induce ATP release via caspase-gated pannexin-1 channels and a caspase/pannexin-1-independent mechanism.J Biol Chem. 2014 Sep 26;289(39):27246-27263. doi: 10.1074/jbc.M114.590240. Epub 2014 Aug 11.
• [190] PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.J Exp Med. 2018 Dec 3;215(12):3094-3114. doi: 10.1084/jem.20180570. Epub 2018 Nov 7.
• [191] TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.Cytokine. 2016 Jun;82:52-7. doi: 10.1016/j.cyto.2015.12.025. Epub 2016 Jan 23.
• [192] NUP98/11p15 translocations affect CD34+ cells in myeloid and T lymphoid leukemias.Leuk Res. 2015 Jul;39(7):769-72. doi: 10.1016/j.leukres.2015.04.014. Epub 2015 May 7.
• [193] RasGRP1 overexpression in T-ALL increases basal nucleotide exchange on Ras rendering the Ras/PI3K/Akt pathway responsive to protumorigenic cytokines.Oncogene. 2016 Jul 14;35(28):3658-68. doi: 10.1038/onc.2015.431. Epub 2015 Nov 9.
• [194] Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma.Cancer Res. 2016 Jun 1;76(11):3387-96. doi: 10.1158/0008-5472.CAN-15-2698. Epub 2016 Apr 5.
• [195] Semaphorin 3F and neuropilin-2 control the migration of human T-cell precursors.PLoS One. 2014 Jul 28;9(7):e103405. doi: 10.1371/journal.pone.0103405. eCollection 2014.
• [196] Vav1: Friend and Foe of Cancer.Trends Cell Biol. 2017 Dec;27(12):879-880. doi: 10.1016/j.tcb.2017.10.004. Epub 2017 Oct 30.
• [197] Neutropenic acute acalculous cholecystitis (AAC) in a 12-year-old boy with T-acute lymphoblastic leukemia successfully managed with conservative treatment.Pediatr Hematol Oncol. 2017 Feb;34(1):24-28. doi: 10.1080/08880018.2016.1265034. Epub 2017 Jan 13.
• [198] TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia.Cancer Discov. 2017 Nov;7(11):1336-1353. doi: 10.1158/2159-8290.CD-17-0267. Epub 2017 Oct 3.